Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study on Specific-Population to Evaluate the Safety and Efficacy of Therapeutic Double-plasmid HBV DNA Vaccine in HBeAg-positive Patients With Chronic Hepatitis B.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Hepatitis B DNA vaccine (Primary) ; Lamivudine
- Indications Hepatitis B
- Focus Therapeutic Use
- 08 Sep 2010 New trial record